Almitrine for treating the hypoxemia of a coronavirus infection
OwnerMichael David Forrestinventor
Life of this patent
Estimating the term…
Abstract
Hypoxemia is an abnormally low O2 concentration in the blood. It can be lethal. When vital organs don't get enough O2 to operate properly. A coronavirus infection can cause hypoxemia. Wherein this is probably the most common cause of coronavirus associated death. COVID-19 has killed millions of people to date. A method comprising the administration of a therapeutically effective amount of almitrine dimesylate to a subject with a coronavirus infection. To treat/ameliorate/reduce/prevent any coronavirus associated hypoxemia in the subject. Therein increasing the subject's chance of survival.
Claims29
Almitrine, and/or a pharmaceutically-acceptable salt, solvate, hydrate or prodrug thereof, e.g. almitrine dimesylate, for use in a method of treating/ameliorating/preventing a coronavirus infection in a subject.
Almitrine, and/or a pharmaceutically-acceptable salt, solvate, hydrate or prodrug thereof, e.g. almitrine dimesylate, for use in a method of treating/ameliorating/preventing at least one respiratory symptom of a coronavirus infection in a subject.
Almitrine, and/or a pharmaceutically-acceptable salt, solvate, hydrate or prodrug thereof, e.g. almitrine dimesylate, for use in a method of treating/ameliorating/preventing the hypoxemia (low PaO2, low blood PO2) of a coronavirus infection in a subject.
Dependencies are inferred from the claim text.